C. Evan Ballantyne

C. Evan Ballantyne

Former Chief Financial OfficeratGain Therapeutics· In proxies 2022–2024

Pay in FY2024-94% from the year before · Gain Therapeutics stock -33.8% the same year

C. Evan Ballantyne was paid $69.1K in FY2024 (Dec), down 94%. Gain Therapeutics stock fell 33.8% that year.

Pay$100 in the stock at the end of FY21 → $40
Pay is from the Summary Compensation Table of each Gain Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Gain TherapeuticsPublic company · 4 yr
    • Former Chief Financial Officer2022 – Present · 4 yrStock in role -79%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?